Scienture Holdings, Inc. announced a securities purchase agreement with institutional investors for the purchase of 3,225,000 shares of common stock.
The offering price is set at $1.20 per share, with expected gross proceeds of approximately $3.9 million before expenses.
Maxim Group LLC is the sole placement agent for the offering, expected to close on August 15, 2025.
Offering Details
3,225,000 shares of common stock at $1.20 per share, gross proceeds of $3.9 million.
Placement Agent
Maxim Group LLC is the sole placement agent for the offering.
Registration Statement
Offering made under effective shelf registration statement on Form S-3 (File No. 333-289198).
Prospectus Information
Shares offered through prospectus supplement and accompanying prospectus.
Legal Disclaimer
Press release does not constitute an offer to sell or solicitation to buy securities.
- The announcement highlights Scienture Holdings' focus on offering novel pharmaceutical products.
- Maxim Group LLC's involvement indicates strategic placement services for the Company's offering.
Scienture Holdings' entry into the registered direct offering reflects its commitment to enhancing value for patients and healthcare systems through specialty pharmaceutical products.